Skip to content Skip to footer
Subscribe Now
PharmaShots Interview SalioGen Therapeutics’ Ray Tabibiazar Shares Insights on Gene Coding Platform
VIEWPOINTS

PharmaShots Interview: SalioGen Therapeutics’ Ray Tabibiazar Shares Insights on Gene Coding Platform

In an interview with PharmaShots, Ray Tabibiazar, M.D., Chief Executive Officer and Chairman, Board of Directors at SalioGen Therapeutics shares his views on the completion of $115M series B financing to advance gene coding platform for genetic diseases Shots: The company has completed $115M series B financing which was co-led by GordonMD global investments and EPIQ capital group. The financing will…
March 8, 2022

Read more

ThoughtSpot_Senior Editor
THOUGHTSPOT

How Pharma 4.0 Influences Cell and Gene Therapy

Pharma 4.0 foresees a manufacturing environment that is mostly automated and barely depends on human labor. Production systems would be interconnected with each other, as well as with supply chain management systems and quality assessment systems, all orchestrated by machine-learning-driven AI control systems. As such, smart factories promise higher productivity, better quality, and enhanced agility.…
March 7, 2022

Read more

Insights+ Key Biosimilars Events of February 2022
INSIGHTS+

Insights+ Key Biosimilars Events of February 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of February, Biocon acquired Viatris’ biosimilars assets for ~$3.335B,…
March 3, 2022

Read more

VIEWPOINTS

PharmaShots Interview: Clario’s Joyce Suhy Shares Insights on PET Imaging Clinical Trials

In an interview with PharmaShots, Joyce Suhy, Senior Vice President, Medical Imaging at Clario shares her views on the PET imaging clinical trials & expands its 2018 collaboration with XingImaging for Alzheimer’s disease and other neurodegenerative diseases Shots: Clario & XingImaging have expanded the collaboration to provide PET imaging clinical trials for neurodegenerative therapeutics in China. The initial study used Amyvid (florbetapir) PET imaging to…
March 1, 2022

Read more

PharmaShots Interview Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
VIEWPOINTS

PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis

In an interview with PharmaShots, Jonathan Wang, Executive Vice President and Head of Business Development at Zai Lab shares his views on the license agreement with Karuna Therapeutics for KarXT (xanomeline-trospium) to treat schizophrenia and psychosis Shots: The companies collaborate to develop, manufacture & commercialize KarXT in Greater China including mainland China, Hong Kong, Macau & Taiwan Zai Lab gets exclusive rights to develop &…
February 28, 2022

Read more

Viewpoints_Senior Editor
VIEWPOINTS

PharmaShots Interview: Boston Scientific’s Ron Morton Shares Insights on the Rezūm Water Vapor Therapy

In an interview with PharmaShots, Ron Morton, Chief Medical Officer, Vice President of Medical Affairs, UroPH at Boston Scientific shares his views on RezĹ«m Water Vapor Therapy to reduces the size of the prostate and provides lasting symptom relief from benign prostatic hyperplasia Shots: The company reported the new data from a survey of 2,000 American men aged ≥60 conducted by…
February 24, 2022

Read more

Viewpoints_Tania Small
VIEWPOINTS

PharmaShots Interview: GSK’s Tania Small Shares Insight on Target the Future Program

In an interview with PharmaShots, Tania Small, Vice President of Global Medical Oncology at GSK shares her views on the launch of Target the Future Program to help address the challenges affecting the multiple myeloma community Shots: The company has launched Target the Future program to educate people in the field of multiple myeloma and address unmet needs in the community A grant of…
February 23, 2022

Read more

PharmaShots Interview Novartis’ Todd Fox Shares Insight on the US FDA's Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis
VIEWPOINTS

PharmaShots Interview: Novartis’ Todd Fox Shares Insight on the US FDA’s Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis

In an interview with PharmaShots, Todd Fox, Global Medical Franchise Head, Immunology Hepatology and Dermatology at Novartis shares his views on Cosentyx in P-III (JUNIPERA) study for the treatment of enthesitis-related arthritis and psoriatic arthritis Shots: The approval is based on the P-III (JUNIPERA) study to evaluate Cosentyx (75/150mg) vs PBO in 86 children & adolescents aged 2 to 18yrs. with ERA…
February 22, 2022

Read more

Exclusive_Nikhil Lalwani_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Nikhil Lalwani of ANI Pharmaceuticals Shares Insight on Purified Cortrophin Gel

In an interview with PharmaShots, Nikhil Lalwani, President, and CEO at ANI Pharmaceuticals shared his views on the launch of Purified Cortrophin Gel for the treatment of multiple chronic autoimmune disorders Shots: The company launches Purified Cortrophin Gel for the treatment of chronic autoimmune disorders, including acute exacerbations of MS, RA, and excess urinary protein due to nephrotic syndrome Cortrophin Gel is an…
February 21, 2022

Read more

Load more